influenza
respiratori
syndrom
caus
three
six
genera
orthomyxovirida
famili
influenza
b
c
put
fourth
genu
influenza
recent
character
propos
influenza
widespread
variou
subtyp
classifi
accord
antigen
variabl
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
virion
consist
segment
neg
sens
genom
encapsid
ribonucleoprotein
complex
surround
matrix
shell
lipid
envelop
contain
two
surfac
glycoprotein
ion
channel
influenza
primari
sourc
human
season
form
diseas
respons
death
per
annum
well
death
caus
pandem
occur
consequ
vaccin
influenza
need
regularli
updat
match
predict
circul
strain
constantli
escap
vaccin
protect
mechan
known
antigen
drift
influenza
primarili
associ
wild
fowlbird
case
major
subtyp
reassort
human
strain
antigen
shift
yield
human
compat
virus
previous
unencount
surfac
epitop
pig
usual
consid
mix
vessel
reassort
express
mixtur
sialic
acid
linkag
influenza
viru
research
often
hinder
requir
expens
biosafeti
precaut
especi
case
highli
pathogen
avian
influenza
hpai
eg
pandem
strain
pseudotyp
pseudotyp
particl
chimer
virus
consist
surrog
viru
core
surround
lipid
envelop
surfac
glycoprotein
anoth
viru
ha
remov
genet
element
viru
studi
replac
suitabl
report
virus
especi
hpai
studi
safer
singl
cycl
system
compar
safeti
pseudotyp
virus
circumv
need
restrict
expens
wide
unavail
highcategori
biosafeti
facil
increas
access
research
group
interest
highli
pathogen
virus
review
systemat
analysi
encompass
wide
rang
peerreview
literatur
english
concern
product
use
pseudotyp
bear
influenza
glycoprotein
date
purpos
review
pseudotyp
defin
replicationdefici
virus
contain
viral
core
one
speci
bear
glycoprotein
anoth
repres
genom
literatur
gather
search
influenza
pseudotyp
use
googl
scholar
ncbi
pubm
result
list
public
expand
follow
cite
refer
final
fall
outsid
pseudotyp
definit
specif
use
influenza
pseudotyp
exclud
section
product
transduct
neutral
review
use
interest
product
pseudotyp
use
immunogen
test
preclin
influenza
vaccin
whether
human
anim
set
includ
univers
vaccin
candid
influenza
serolog
studi
measur
seropreval
benefit
manuscript
also
help
inform
process
valid
pseudotypebas
assay
clinic
endpoint
furthermor
studi
util
chimer
ha
protein
order
differenti
stalk
head
direct
antibodi
discuss
core
associ
genom
contain
report
backbon
pseudotyp
system
use
studi
properti
select
entri
protein
use
core
lentivir
human
immunodefici
viru
hiv
gammaretrovirus
murin
leukemia
viru
mlv
predomin
influenza
pseudotyp
literatur
recent
develop
system
involv
rhabdovirus
particular
vesicular
stomat
viru
vsv
also
use
produc
pseudotyp
core
promis
result
retrovir
lentivir
vector
complex
system
explain
simpl
term
specif
product
use
pseudotyp
pseudotyp
core
vector
system
review
detail
primari
gene
provid
retrovir
lentivir
system
gag
pol
case
hiv
gag
provid
structur
protein
wherea
pol
provid
integras
revers
transcriptas
conjunct
proteas
requir
cleavag
matur
distinct
protein
respect
polypeptid
chain
report
construct
associ
respect
core
base
psi
packag
element
incorpor
vector
design
process
make
specif
surrog
speci
use
human
immunodefici
viru
core
deriv
sever
differ
origin
laboratori
group
first
gener
vector
well
repres
commonli
use
defici
provir
clone
deriv
pnl
precursor
inhibitori
frame
shift
env
vpr
gene
well
luciferas
report
gene
clone
nef
entir
construct
incorpor
progeni
pseudotyp
vector
life
cycl
mimic
hiv
use
element
allow
encapsid
nascent
pseudotyp
long
termin
repeat
ltr
region
bear
promot
aid
tat
permit
express
viral
protein
integr
host
genom
rev
respons
element
rre
allow
nuclear
export
viral
messeng
rna
mrna
includ
report
gene
transcript
measur
output
system
due
incorpor
hiv
core
gene
integr
construct
report
transduc
cell
may
possibl
produc
luciferas
contain
core
alongsid
transcrib
enzym
could
potenti
interfer
luciferas
activ
anoth
commonli
use
hiv
core
vector
pcmv
relat
pcmv
still
contain
intact
vif
vpr
vpu
nef
gene
approach
use
second
gener
hiv
vector
also
origin
pcmv
vector
modifi
clone
lack
sequenc
well
env
vif
nef
vpu
vpr
gene
wide
use
articl
studi
cytomegaloviru
promot
use
lieu
ltrbase
promot
mean
provid
necessari
gene
product
core
provir
packag
element
ltr
rre
transfer
separ
plasmid
bear
report
gene
thu
report
construct
incorpor
nascent
virion
integr
transduc
cell
genom
whereupon
ltr
rre
act
enhanc
express
case
commonli
use
firefli
luciferas
green
fluoresc
protein
gfp
plasmid
pcsflw
pcsgw
safeti
compon
incorpor
delet
ltr
promot
region
creat
call
selfinactiv
sin
vector
third
gener
vector
also
use
instanc
hiv
structur
accessori
gene
separ
rev
provid
ci
addit
plasmid
third
gener
invitrogen
virapow
lentivir
express
system
use
sever
case
use
plasmid
murin
leukemia
viru
core
less
wide
use
provid
similar
gag
pol
element
hiv
vector
one
mlv
core
use
consist
gag
pol
effect
cmv
promot
vector
share
across
variou
laboratori
instanc
vector
origin
pci
n
b
nb
differenti
restrict
certain
murin
cell
base
mous
resist
gene
allel
report
use
system
deriv
clontech
vector
lncx
anoth
describ
mlv
plasmid
pkatgagpolatg
origin
ecotrop
moloney
mlv
strain
minor
differ
observ
pseudotyp
hiv
mlv
core
influenza
glycoprotein
therefor
question
core
use
produc
pseudotyp
often
choic
prefer
avail
see
figur
schemat
represent
packag
construct
vector
recombin
vsv
virus
produc
express
gfp
place
resid
vsv
envelop
glycoprotein
vsvg
certain
case
ha
na
simpli
ha
also
ad
vsv
genom
addit
produc
replicationcompet
viru
promot
gfp
product
infect
cell
recombin
virus
limit
singl
cycl
replic
lack
safeti
element
found
within
system
safer
vsvbase
altern
involv
transfect
surfac
protein
encod
plasmid
hana
cell
subsequ
infect
recombin
vsv
way
one
produc
vsv
pseudotyp
influenza
surfac
protein
lack
entryglycoprotein
resid
genom
render
second
gener
viru
infectionincompet
output
pseudotyp
system
base
incorpor
report
mimic
genom
surrog
viru
case
hiv
mlv
surrog
report
often
incorpor
pseudotyp
rna
form
upon
transduct
revers
transcrib
transloc
nucleu
integr
host
cell
genom
report
produc
host
cell
use
measur
transduct
effici
primari
report
use
influenza
pseudotyp
firefli
deriv
luciferas
rel
luminesc
unit
rlu
rel
luciferas
activ
rla
use
output
measur
lyse
transduc
cell
ad
substrat
luciferas
enzym
signal
read
use
luminomet
green
fluoresc
protein
also
commonli
use
case
transduct
effici
determin
count
number
fluoresc
cell
via
epifluoresc
microscopi
fluorescenceactiv
cell
sorter
fac
report
lacz
well
gaussia
renilla
luciferas
also
use
lesser
extent
codon
optim
employ
sever
commerci
synthes
gene
sometim
use
concurr
extract
wild
type
viral
sequenc
depend
avail
genscript
gene
art
integr
dna
technolog
recurs
pcr
use
case
produc
end
product
context
pseudotyp
product
codon
optim
perform
base
assumpt
conform
codonbia
within
produc
cell
increas
product
protein
pseudotyp
yield
wild
type
influenza
viru
na
requir
exit
influenza
pseudotyp
via
cleavag
surfac
sialic
acid
molecul
produc
cell
howev
common
circumv
requir
na
express
pseudotyp
product
treatment
cultur
cell
line
commerci
exogen
bacteri
na
h
transfect
h
time
period
requir
optim
allow
maxim
bud
pseudotyp
minim
loss
transduct
produc
cell
exogen
na
treatment
often
use
neutral
studi
order
prevent
na
direct
antibodi
provid
neutral
signal
howev
sever
studi
opt
incorpor
na
plasmid
influenza
kan
apuerto
sever
recent
articl
character
sialic
acid
bind
attribut
neuraminidas
share
particular
genet
characterist
new
mutat
character
strain
shown
rescu
habind
defici
virus
mutat
present
rang
strain
includ
repres
pandem
chicken
also
possibl
incorpor
ion
channel
influenza
pseudotyp
order
studi
effect
product
process
howev
role
acidif
wild
type
influenza
viru
core
requir
dissoci
pseudotyp
core
deriv
noninfluenza
virus
achiev
releas
genet
materi
ie
luciferas
report
gene
transcript
differ
mechan
therefor
requir
product
influenza
pseudotyp
despit
shown
effect
yield
infect
report
incorpor
increas
pseudotyp
particl
yield
afpvrostock
pseudotyp
shown
influenc
bud
wild
type
influenza
consequ
may
mechan
express
increas
report
pseudotyp
yield
ha
produc
traffick
secretori
pathway
requir
proteolyt
cleavag
order
becom
fusion
compet
proteolyt
cleavag
mediat
certain
host
cell
proteas
restrict
certain
subtyp
epitheli
cell
requir
proteas
express
achiev
natur
wild
type
infect
cleavag
compon
must
incorpor
pseudotyp
product
workflow
order
achiev
optim
yield
produc
cell
line
requir
proteas
either
express
express
suffici
level
make
pseudotyp
fusion
compet
order
mimic
proteolyt
properti
natur
host
cell
influenza
proteas
encod
plasmid
transfect
alongsid
requisit
plasmid
order
induc
transient
express
within
timefram
product
pseudotyp
serin
transmembran
proteas
human
airway
trypsin
hat
cleav
wild
type
influenza
use
success
sever
studi
pseudotyp
product
anoth
serin
proteas
also
use
success
cleav
wild
type
influenza
lentivir
pseudotyp
howev
addit
proteas
encod
plasmid
sidestep
cleavag
postproduct
use
tosyl
phenylalanyl
chloromethyl
keton
tpck
treat
trypsin
tpck
inhibit
less
specif
proteolyt
element
chymotrypsin
restrict
treatment
process
cleavag
peptid
bond
requir
ha
matur
tpcktrypsin
concentr
use
product
pseudotyp
gener
rang
howev
one
studi
report
increas
transduct
use
concentr
pseudotyp
incub
rang
min
room
temperatur
usual
h
tpcktrypsin
treatment
typic
carri
hour
transduct
enzym
neutral
transduct
use
commerci
trypsin
inhibitor
case
origin
soybean
ha
deriv
hpai
strain
contain
polybas
cleavag
sequenc
protein
cleav
wider
rang
proteas
ubiquit
cell
allow
omiss
proteas
plasmid
tpcktrypsin
treatment
hpai
pseudotyp
product
case
polybas
cleavag
site
hpai
strain
integr
attempt
produc
pseudotyp
without
proteas
plasmid
requir
give
strain
similar
entri
characterist
see
figur
repres
draw
pseudotyp
product
process
differ
core
use
consider
variat
studi
regard
choic
express
plasmid
particular
system
establish
within
research
group
network
inherit
previou
studi
often
depend
collabor
gift
popular
system
employ
involv
multipl
plasmid
cotransfect
approach
use
separ
plasmid
ha
report
retrovir
gag
pol
core
gene
gene
clone
rang
express
plasmid
phcmv
pcagg
kozak
consensu
sequenc
rare
mention
defin
one
studi
kozak
consensu
sequenc
deriv
kan
plasmid
use
addit
plasmid
encod
na
sometim
use
studi
relev
aspect
influenza
infect
pseudotyp
product
rare
case
neutral
one
studi
increas
pseudotyp
product
achiev
express
use
lentivir
core
increas
achiev
mlv
core
use
plasmid
ratio
crucial
pseudotyp
product
specif
plasmid
use
well
transfect
method
order
attain
highest
qualiti
yield
optim
requir
typic
core
ha
report
plasmid
ratio
howev
ha
na
ratio
rang
proteas
gene
bear
plasmid
hat
often
present
concentr
ha
eg
ha
plasmid
proteas
plasmid
calcium
phosphat
precipit
requir
highest
plasmid
input
much
plasmid
per
mm
dish
use
wherea
method
fugen
polyethylenimin
pei
lipofectamin
requir
quantiti
plasmid
per
mm
dish
plasmid
ratio
differenti
affect
composit
plasmid
therefor
quantiti
use
produc
pseudotyp
literatur
justifi
base
optim
carri
particular
laboratori
produc
cell
line
use
pseudotyp
product
predominantli
human
embryon
kidney
cell
transform
larg
antigen
cell
highli
suscept
transfect
make
good
retrovir
packag
cell
clone
cell
line
also
extens
use
produc
hightit
influenza
pseudotyp
cell
line
use
includ
cell
invitrogen
use
product
pseudotyp
mention
cell
confluenc
transfect
vari
cell
subcultur
h
transfect
cell
monolay
grown
dish
rang
mm
occasion
studi
use
flask
multiwel
plate
transfect
usual
carri
use
medium
serum
fetal
bovin
serum
fb
concentr
method
studi
use
follow
chemic
transfect
reagent
lipofectamin
lipofectamin
thermo
fisher
scientif
fugenehd
promega
pei
jetpei
polyplu
transfect
calcium
phosphat
precipit
choic
reagent
base
optim
lab
protocol
cost
well
cytotox
reagent
depend
requir
pseudotyp
product
reagent
calcium
phosphat
precipit
popular
calcium
phosphat
precipit
wellestablish
transfect
method
mammalian
cell
develop
graham
van
der
eb
method
involv
mix
compar
high
amount
plasmid
dna
calcium
chlorid
ad
mixtur
slowli
buffer
salin
solut
mixtur
incub
room
temperatur
whereupon
posit
charg
dna
calcium
phosphat
precipit
form
charg
allow
precipit
associ
neg
charg
cell
membran
enter
endocytosi
phagocytosi
calcium
phosphat
precipit
process
sensit
small
differ
ph
polyethylenimin
polymer
cation
first
evalu
transfect
capabl
pei
act
rang
ph
valu
associ
dna
produc
complex
overal
posit
charg
allow
interact
cell
membran
entri
endocytosi
pei
shown
aid
deliveri
nucleic
acid
cell
nucleu
transfect
cell
origin
report
state
pei
noncytotox
optim
concentr
transfect
howev
use
pei
transfect
commonplac
chang
cell
cultur
medium
within
h
transfect
jetpei
manufactur
linear
form
pei
suit
highthroughput
assay
lipofectamin
lipofectamin
cation
lipid
sold
invitrogen
allow
deliveri
nucleic
acid
vector
host
cell
format
posit
charg
liposom
liposom
contain
pseudotyp
vector
abl
fuse
cell
membran
due
posit
charg
lipid
constitut
lipofectamin
among
expens
transfect
reagent
use
influenza
pseudotyp
product
benefit
use
method
readili
appar
cost
reagent
consid
fugenehd
cation
lipid
complex
low
cell
cytotox
allow
laboratori
avoid
replac
transfect
medium
may
allow
increas
final
titer
pseudotyp
harvest
fugenehd
shown
effici
transfect
reagent
tabl
show
list
transfect
reagent
cytotox
cost
plasmid
input
requir
transfect
cytotox
reagent
use
medium
replenish
h
posttransfect
studi
state
media
typic
replenish
overnight
incub
media
replac
also
accompani
pb
wash
rhabdovirus
use
pseudotyp
cell
line
wash
use
pb
h
transfect
influenza
surfac
glycoprotein
plasmid
helper
viru
ad
h
later
helper
viru
contain
medium
replac
pb
wash
step
sodium
butyr
compound
increas
cell
prolifer
pseudotyp
product
use
sever
studi
concentr
rang
mm
pseudotyp
harvest
variou
time
interv
typic
h
posttransfect
sometim
also
h
supernat
taken
transfect
cell
monolay
pass
filter
remov
cell
debri
store
mani
case
centrifug
low
high
speed
use
concentr
harvest
viru
one
studi
demonstr
influenza
pseudotyp
stabl
five
cycl
retain
infect
keep
pseudotyp
supernat
month
similar
effect
howev
storag
led
reduct
infect
case
environ
lack
reliabl
refriger
facil
pseudotyp
lyophil
store
rang
increas
temperatur
humid
maintain
viabil
concentr
adequ
use
neutral
assay
see
figur
detail
depict
method
use
product
base
pseudotyp
employ
articl
cite
review
previous
mention
luciferas
report
pseudotyp
rlu
read
deriv
titrat
use
secondari
measur
pseudotyp
concentr
within
sampl
howev
rlu
read
depend
mani
variabl
surround
cell
particular
luminomet
use
pseudotyp
titrat
serial
dilut
harvest
supernat
plate
incub
h
rlu
measur
lyse
transduc
cell
ad
luciferin
luciferas
substrat
use
calcul
rlu
per
well
rluml
origin
sampl
revers
transcriptas
quantit
pcr
qrtpcr
also
employ
order
estim
transfect
gene
copi
well
mrna
copi
cell
method
often
use
conjunct
other
describ
section
order
compar
measur
pseudotyp
quantiti
mani
studi
pseudotyp
input
normal
via
enzymelink
immunosorb
assay
elisa
detect
princip
compon
hiv
core
howev
core
bud
independ
surfac
ha
method
detect
core
lack
envelop
glycoprotein
well
core
belong
transduct
compet
pseudotyp
pseudotyp
ha
also
detect
use
elisa
use
normal
pseudotyp
input
quantif
hemagglutin
assay
also
use
frequent
western
blot
use
case
determin
amount
glycoprotein
hiv
pseudotyp
sampl
also
use
wider
rang
studi
ascertain
glycoprotein
hiv
express
vast
major
studi
involv
neutral
assay
titrat
transduc
plate
cell
mdck
per
well
howev
amount
cell
rang
instanc
mdcklondon
cell
also
use
wherea
cell
frequent
use
vsvbase
pseudotyp
infect
due
compar
suscept
special
cell
overexpress
sialic
acid
mdcksiat
also
use
compar
parent
cell
presenc
solubl
ha
one
case
transduct
carri
transpar
cultur
plate
lysat
transfer
luminomet
plate
analysi
import
pseudotyp
input
batch
batch
variat
highlight
garcia
et
al
studi
suggest
rlu
least
per
well
use
ensur
antibodi
titer
independ
pseudotyp
input
steadyglo
brightglo
promega
common
sourc
luciferin
expens
two
substrat
also
serv
secondari
purpos
lyse
cell
releas
express
luciferas
enzym
dispar
record
equip
use
articl
studi
review
without
requir
inform
reproduct
studi
hamper
variabl
relat
plate
read
inform
relat
color
manufactur
plate
import
quantif
viabl
pseudotyp
order
prevent
introduct
variabl
laboratori
logist
difficult
standard
neutral
assay
equip
across
laboratori
studi
influenza
would
bring
benefit
interpret
research
data
standard
plate
read
equip
also
requir
order
ensur
compar
data
obtain
differ
machin
read
experi
highthroughput
approach
use
evalu
antivir
compound
effect
pseudotyp
transduct
test
wide
rang
uniqu
compound
singl
assay
perform
plate
polybren
hexamethrin
bromid
polyfect
qiagen
use
sever
studi
order
increas
transduct
effici
mgml
polybren
ad
viru
virusantibodi
mix
addit
cell
titrat
neutral
assay
incub
two
studi
spinocul
use
increas
transduct
rate
achiev
increas
transduct
rate
pseudotyp
cell
centrifug
rpm
h
rpm
h
pseudotyp
neutral
assay
pmn
usual
carri
white
plate
measur
amount
antibodi
medium
serial
dilut
across
plate
incub
set
amount
quantifi
viru
medium
usual
viru
antibodi
ratio
incub
carri
min
h
target
cell
ad
well
subsequ
plate
left
incub
h
cellonli
control
well
known
posit
neg
sera
standard
use
benchmark
neutral
assay
see
figur
depict
pmn
assay
quantiti
pseudotyp
use
neutral
assay
normal
base
elisa
rang
ngml
rlu
rla
valu
per
well
use
plate
sometim
conjunct
normal
qpcr
method
estim
copi
number
per
set
volum
origin
viral
supernat
also
use
import
note
rlu
base
valu
affect
makeup
plasmid
bear
ha
gene
well
multitud
factor
luminomet
use
measur
transduct
antibodi
input
vari
depend
avail
especi
take
account
possibl
repeat
replic
antibodi
primarili
dilut
dulbecco
modifi
eagl
medium
dmem
without
fb
across
plate
occasion
three
four
dilut
experi
mention
start
antibodi
concentr
rang
state
serum
complement
inactiv
vari
min
h
pseudotypeantibodi
incub
time
gener
consist
studi
h
transduct
time
vari
h
increment
h
output
measur
posit
sera
specif
commerci
antibodi
requir
posit
control
compar
test
sera
use
normal
assay
see
approach
toward
valid
standard
refer
sera
nation
institut
biolog
standard
control
nibsc
offic
intern
de
epizooti
oie
anim
plant
health
agenc
apha
previous
ahvla
us
food
drug
administr
fda
regularli
use
antibodi
effect
display
use
one
mani
inhibitori
concentr
numer
valu
relat
percentag
point
particular
studi
calcul
exampl
valu
repres
concentr
antibodi
reduc
rlu
read
compar
transduct
control
control
essenti
calcul
inhibit
benchmark
cellonli
control
incub
cell
viru
absenc
sera
hemagglutinationinhibit
assay
hi
assay
use
pseudotyp
util
procedur
wild
type
viru
quantifi
amount
viral
sampl
determin
hemagglutin
assay
phosphat
buffer
salin
ad
serial
dilut
sera
plate
chickenturkey
red
blood
cell
suspens
ad
min
h
hi
plate
score
agglutin
pseudotyp
input
adjust
accord
guidelin
four
hemagglutin
unit
sera
treat
receptor
destroy
enzym
inactiv
nonspecif
inhibit
agglutin
postattach
neutral
assay
use
identifi
antibodi
neutral
ha
bound
sialic
acid
oh
et
al
modifi
postattach
assay
origin
develop
edward
dimmock
allow
wild
type
influenza
viru
replac
influenza
pseudotyp
particl
assay
pseudotyp
particl
incub
cell
enabl
synchron
attach
viru
sialic
acid
cell
surfac
block
viral
endocytosi
dilut
serum
ad
follow
anoth
incub
plate
transfer
permit
transduct
transduct
measur
use
approach
taken
neutral
assay
antibodi
detect
assay
neutral
activ
via
abil
imped
endocytosi
step
subsequ
ha
conform
chang
necessari
fusion
antibodi
neutral
activ
imped
viral
attach
produc
neg
result
assay
postattach
assay
use
evalu
neutral
capac
stalkdirect
antibodi
inhibit
viral
attach
issu
crossreact
sera
rais
previous
tradit
serolog
assay
serum
sampl
produc
inject
wildtyp
viru
mice
shown
lead
presenc
interf
antibodi
direct
toward
na
epitop
expect
pmn
suffer
problem
crossreact
import
issu
must
address
futur
order
strengthen
use
assay
competitor
current
gold
standard
reproduc
major
issu
field
serolog
serum
sampl
often
finit
lead
inabl
reproduc
experi
result
context
origin
publish
howev
standard
method
product
titrat
neutral
use
common
refer
standard
possibl
minim
variat
experi
research
group
comparison
made
pmn
assay
tradit
serolog
assay
mix
result
sever
articl
report
increas
human
antibodi
titer
comparison
microneutr
mn
base
result
buchi
et
al
show
correl
pseudotyp
mn
spearman
p
also
seen
du
et
al
wang
et
al
latter
present
valu
strain
alberini
et
al
compar
pmn
assay
hemagglutinationinhibit
hi
singl
radial
hemolysi
srh
mn
assay
use
differ
human
serum
sampl
pearson
correl
test
produc
signific
correl
p
antibodi
titer
calcul
assay
correl
coeffici
pmn
hi
srh
mn
assay
respect
furthermor
correl
mn
pmn
allow
establish
threshold
pmn
titer
could
base
pmn
data
analyz
base
threshold
show
protect
titer
patient
adjuv
vaccin
second
dose
booster
respect
qiu
et
al
show
rang
correl
hi
pmn
use
differ
ha
subtyp
correl
well
r
p
poorli
r
p
r
p
wherea
correl
r
p
addit
studi
hi
pmn
correl
well
qiu
et
al
case
spearman
r
p
well
whittl
et
al
p
signific
correl
p
r
also
report
srh
pmn
use
equin
influenza
pseudotyp
sera
anoth
studi
show
relationship
rlu
ha
content
approach
toward
standard
pmn
follow
procedur
requir
mn
standard
standard
mn
gener
focus
use
pool
serum
sampl
refer
standard
pandem
pdm
standard
establish
assign
potenc
iuml
second
pool
sera
refer
standard
exist
success
use
number
studi
cut
valu
posit
neg
neutral
sera
exist
set
refer
standard
consider
research
stalk
region
ha
relat
vaccin
design
immun
influenza
variou
stalkdirect
monoclon
antibodi
mab
character
open
potenti
use
chimer
ha
test
presenc
similar
antibodi
serum
sampl
stalkdirect
antibodi
first
identifi
crossreact
mous
monoclon
antibodi
identifi
found
inhibit
fusion
sever
ha
subtyp
sinc
mani
studi
focus
stalkdirect
antibodi
neutral
multipl
divers
subtyp
influenza
howev
rang
heterosubtyp
immun
depend
characterist
epitop
antibodi
test
influenc
subtyp
clade
whether
neutral
group
influenza
stalk
region
ha
conserv
variabl
globular
head
vast
major
neutral
antibodi
direct
residu
head
mediat
attach
viru
target
cell
bind
sialic
acid
fusion
peptid
stalk
ha
crucial
ha
function
order
test
neutral
stalk
antibodi
studi
employ
varieti
chimer
ha
construct
bear
stalk
head
differ
subtyp
concept
behind
revolv
around
use
ha
head
larg
unreact
antibodi
use
assay
util
approach
neutral
respons
detect
absenc
headdirect
neutral
sever
hybrid
construct
pseudotyp
use
hiv
core
gener
construct
pcr
amplif
incorpor
complementari
restrict
site
allow
ligat
differ
segment
ha
gene
wider
varieti
use
revers
genet
approach
toward
develop
wild
type
viru
bear
chimer
chimer
ha
promis
candid
test
univers
vaccin
tabl
display
region
subtyp
use
construct
chimer
hemagglutinin
figur
visual
chimer
ha
construct
form
comput
model
pseudotyp
neutral
assay
offer
safeti
use
pseudotyp
sensit
mn
assay
valid
standard
assay
requir
establish
assay
offer
robust
sensit
mean
interrog
influenza
vaccin
trial
head
stalktarget
antibodi
product
vaccin
elicit
stalktarget
antibodi
may
time
lead
univers
vaccin
prevent
death
season
influenza
emerg
pandem
strain
recent
pdm
caus
estim
death
pmn
current
offer
opportun
batch
test
vaccin
commerci
antibodi
absenc
standard
furthermor
abil
pmn
assay
includ
chimer
ha
also
na
allow
pmn
use
explain
pathogen
season
pandem
influenza
strain
perhap
elucid
antigen
evolut
influenza
field
gene
therapi
progress
influenza
pseudotyp
benefit
design
even
safer
effect
vector
sophist
system
develop
may
becom
easili
standard
compar
wild
type
viru
one
aspect
gene
therapi
may
benefit
field
influenza
use
viral
entri
protein
target
deliveri
nucleic
acid
specif
cell
vaccin
deliveri
system
one
deliveri
system
studi
use
influenza
pseudotyp
transduc
respiratori
epitheli
cell
mice
nasal
administr
promis
result
indic
method
could
use
treatment
cystic
fibrosi
similar
studi
present
rescu
ciliari
function
use
influenza
pseudotyp
contain
therapeut
cdna
pseudotypebas
influenza
gene
deliveri
vaccin
also
becom
widespread
sever
candid
alreadi
cite
review
baculoviru
pseudotyp
vsvg
use
success
express
ha
mammalian
cell
provid
efficaci
vaccin
test
chicken
mice
origin
popular
vector
transgen
express
insect
cell
baculoviru
shown
use
tool
vaccin
product
mammalian
cell
wu
et
al
deliveri
achiev
vsvg
incorpor
baculoviru
effect
polyhedron
promot
ha
effect
cmv
promot
order
achiev
express
subsequ
infect
mammalian
cell
interest
gene
deliveri
system
could
use
method
introduct
pseudotyp
gene
cell
vsvg
bear
baculoviru
lieu
cytotox
transfect
reagent
pseudotyp
vaccin
develop
contain
modifi
ha
gene
allow
express
transduc
cell
lack
viral
rna
sequenc
requir
replic
approach
yield
particl
bear
desir
glycoprotein
case
apuerto
consequ
induc
robust
tcell
respons
given
mice
via
inhal
reduct
sever
symptom
also
seen
mice
infect
differ
subtyp
approach
demonstr
flexibl
pseudotyp
platform
establish
method
includ
adenoviru
modifi
vaccinia
virus
eg
modifi
vaccinia
ankara
may
present
attract
option
deliveri
influenza
gene
review
great
depth
pseudotyp
use
immunogen
bear
test
mice
candid
vaccin
elicit
high
level
antiha
antibodi
determin
hi
mice
vaccin
surviv
despit
weight
loss
approxim
wherea
nonvaccin
group
lost
approxim
bodyweight
perish
day
viru
challeng
similar
approach
taken
et
al
product
pseudotyp
viruslik
particl
immunogen
test
mice
influenza
pseudotyp
could
also
use
vaccin
design
use
integras
defect
lentivir
vector
technolog
defect
lentivir
vector
technolog
allow
transduct
target
cell
mainten
episom
report
construct
without
integr
genom
approach
may
bring
benefit
reduc
chanc
interrupt
host
gene
eventu
dilut
deliv
gene
time
see
figur
depict
variou
pseudotypebas
vaccin
immunogen
cell
monolay
confluenc
transfect
use
calcium
phosphat
precipit
medium
contain
fb
plasmid
ratio
optim
base
plasmid
use
use
second
gener
hiv
packag
construct
recommend
na
encod
plasmid
use
exogen
na
ad
h
posttransfect
induc
releas
pseudotyp
supernat
harvest
h
posttransfect
filter
filter
filter
supernat
kept
singl
use
aliquot
longterm
storag
requir
titrat
carri
use
luciferasebas
transduct
white
plate
elisa
method
quantif
quantif
pseudotyp
particl
use
luciferasebas
transduct
involv
serial
dilut
pseudotyp
fb
medium
cell
ad
volum
result
solut
incub
h
incub
period
luciferas
substrat
ad
well
rlu
valu
read
cell
vsvg
bear
pseudotyp
use
neg
posit
control
serum
sampl
serial
dilut
across
plate
media
pseudotyp
viru
ad
volum
concentr
rlu
h
incub
mdck
cell
ad
volum
plate
incub
h
luciferas
substrat
ad
well
rlu
valu
read
standard
ideal
use
form
neutral
antibodi
pool
serum
sampl
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
